201. Deficient mismatch repair and RAS mutation in colorectal carcinoma patients: a retrospective study in Eastern China
- Author
-
Huamin Liu, Wenwen Ran, Yujing Xiao, Xiangyan Zhang, Yujun Li, Xiaonan Wang, Jie Wu, Lili Wang, Xiaoming Xing, and Hong Li
- Subjects
0301 basic medicine ,Neuroblastoma RAS viral oncogene homolog ,Oncology ,medicine.medical_specialty ,Colorectal cancer ,lcsh:Medicine ,Gastroenterology and Hepatology ,medicine.disease_cause ,Deficient mismatch repair (dMMR ) ,General Biochemistry, Genetics and Molecular Biology ,Clinicopathological characteristics ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Pathology ,medicine ,Stage (cooking) ,Family history ,business.industry ,General Neuroscience ,lcsh:R ,KRAS mutation ,General Medicine ,Prognosis ,medicine.disease ,Colorectal carcinoma ,NRAS mutation ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation (genetic algorithm) ,Immunohistochemistry ,DNA mismatch repair ,KRAS ,General Agricultural and Biological Sciences ,business ,Medical Genetics - Abstract
Objectives To investigate the frequency and prognostic role of deficient mismatch repair (dMMR) and RAS mutation in Chinese patients with colorectal carcinoma. Methods Clinical and pathological information from 813 patients were reviewed and recorded. Expression of mismatch repair proteins was tested by immunohistochemistry. Mutation analyses for RAS gene were performed by real-time polymerase chain reaction. Correlations of mismatch repair status and RAS mutation status with clinicopathological characteristics and disease survival were determined. Results The overall percentage of dMMR was 15.18% (121/797). The proportion of dMMR was higher in patients p p p p p p RAS mutation rate was 45.88%, including 42.56% (346/813) KRAS mutation and 3.69% (30/813) NRAS mutation (including three patients with mutations in both). KRAS mutation was significantly associated with mucinous production (p p p p KRAS mutation, however, dMMR tumors were less likely to have NRAS mutation. Moreover, dMMR, KRAS and NRAS mutation were not prognostic factors for stage I–III colorectal carcinoma. Conclusions This study confirms that the status of molecular markers involving mismatch repair status and RAS mutation reflects the specific clinicopathological characteristics of colorectal carcinoma.
- Published
- 2018